




# HIV Disease, Stage 3 (AIDS) 2022


# Stage 3 (AIDS) Classifications, Deaths (Any Cause), and Persons Living with Diagnosed HIV Ever Classified as Stage 3 (AIDS), 1985–2022—United States and 6 Territories and Freely Associated States



*Note.* Deaths of persons with HIV disease ever classified as stage 3 (AIDS) may be due to any cause. Data include persons of all ages. Data for the year 2022 are preliminary and based on deaths reported to CDC as of December 2023. Data for 2020, which coincided with the onset of the COVID-19 pandemic, should be interpreted with caution. The pandemic had a significant impact on access to HIV testing, care, and related services, and case surveillance activities in state and local jurisdictions. As the COVID-19 pandemic lasted beyond 2020, readers should also consider the potential influence of these pandemic effects on U.S. public health systems when interpreting HIV data for 2021–2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see [https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess\\_deaths.htm](https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm).



# Rates of Stage 3 (AIDS) Classifications and Deaths (Any Cause) of Persons with Diagnosed HIV Ever Classified as Stage 3 (AIDS), 1985–2022—United States and 5 Territories and Freely Associated States



*Note.* Deaths of persons with HIV disease ever classified as stage 3 (AIDS) may be due to any cause. Data include persons of all ages. Data for the year 2022 are preliminary and based on deaths reported to CDC as of December 2023. Data for 2020, which coincided with the onset of the COVID-19 pandemic, should be interpreted with caution. The pandemic had a significant impact on access to HIV testing, care, and related services, and case surveillance activities in state and local jurisdictions. As the COVID-19 pandemic lasted beyond 2020, readers should also consider the potential influence of these pandemic effects on U.S. public health systems when interpreting HIV data for 2021–2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see [https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess\\_deaths.htm](https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm).



## Stage 3 (AIDS) Classifications and Deaths of Persons with Stage 3 (AIDS), by Age at Classification or Death (Any Cause), Cumulative as of Year-End 2022—

Age at Classification or Death	Classifications		Deaths	
	No.	%	No.	%
<13	10,050	0.7	5,195	0.6
13–14	1,583	0.1	305	0.0
15–19	10,614	0.8	1,393	0.2
20–24	60,877	4.5	11,074	1.4
25–29	160,634	11.9	51,541	6.4
30–34	247,442	18.3	109,964	13.6
35–39	263,167	19.5	138,387	17.1
40–44	221,020	16.4	133,469	16.5
45–49	155,829	11.5	109,902	13.6
50–54	99,251	7.3	86,107	10.6
55–59	59,009	4.4	64,556	8.0
60–64	32,885	2.4	44,605	5.5
≥65	28,637	2.1	53,868	6.6
<b>Total</b>	<b>1,350,998</b>	<b>100</b>	<b>810,366</b>	<b>100</b>

Note. Deaths of persons with HIV disease, stage 3 (AIDS) may be due to any cause. Cumulative data are from the beginning of the epidemic through 2022.



## Stage 3 (AIDS) Classifications and Deaths (Any Cause) of Persons with Stage 3 (AIDS), by Race/Ethnicity, Cumulative as of Year-End 2022— United States and 6 Territories and Freely Associated States

Race/ethnicity	Classifications		Deaths	
	No.	%	No.	%
American Indian/Alaska Native	3,664	0.8	2,240	0.3
Asian <sup>a</sup>	11,268	0.8	4,120	0.5
Black/African American	537,763	39.8	324,391	40.0
Hispanic/Latino <sup>b</sup>	289,842	21.5	150,464	18.6
Native Hawaiian/other Pacific Islander	877	0.1	451	0.1
White	452,648	33.5	305,807	37.7
Multiracial	54,861	4.1	22,848	2.8
<b>Total<sup>c</sup></b>	<b>1,350,998</b>	<b>100</b>	<b>810,366</b>	<b>100</b>

*Note.* Deaths of persons with HIV disease, stage 3 (AIDS) may be due to any cause. Cumulative data are from the beginning of the epidemic through 2022.

<sup>a</sup> Includes Asian/Pacific Islander legacy cases

<sup>b</sup> Hispanic/Latino persons can be of any race.

<sup>c</sup> Data include persons whose race/ethnicity is unknown.



# Stage 3 (AIDS) Classifications and Deaths (Any Cause) of Persons with Stage 3 (AIDS) among Males Aged $\geq 13$ Years, Based on Sex Assigned at Birth, by Transmission Category, Cumulative as of Year-End 2022—United States and 6 Territories and Freely Associated States

Transmission Category <sup>a</sup>	Classifications		Deaths	
	No.	%	No.	%
Male-to-male sexual contact (MMSC) <sup>b</sup>	651,296	61.4	367,550	56.5
Injection drug use (IDU) <sup>c</sup>	198,680	18.7	156,721	24.1
MMSC <sup>b</sup> and IDU <sup>c</sup>	98,594	9.3	64,842	10
Heterosexual contact <sup>d</sup>	100,102	9.4	51,537	7.9
Perinatal <sup>e</sup>	1,529	0.1	810	0.1
Other <sup>f</sup>	10,656	1	9,208	1.4
<b>Total<sup>g</sup></b>	<b>1,060,857</b>	<b>100</b>	<b>650,668</b>	<b>100</b>

Note. Deaths of persons with HIV disease, stage 3 (AIDS) may be due to any cause. Data have been statistically adjusted to account for missing transmission category. Cumulative data are from the beginning of the epidemic through 2022.

<sup>a</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.

<sup>b</sup> Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>c</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>d</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV.

<sup>e</sup> Individuals were aged  $\geq 13$  years at time of stage 3 classification or death.

<sup>f</sup> Other risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>g</sup> Because column totals for numbers were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.



# Stage 3 (AIDS) Classifications and Deaths (Any Cause) of Persons with Stage 3 (AIDS) among Females Aged ≥13 Years, Based on Sex Assigned at Birth, by Transmission Category, Cumulative as of Year-End 2022—United States and 6 Territories and Freely Associated States

Transmission Category <sup>a</sup>	Classifications		Deaths	
	No.	%	No.	%
Injection drug use (IDU) <sup>b</sup>	97,419	34.8	69,170	44.8
Heterosexual contact <sup>c</sup>	176,024	62.8	80,484	52.1
Perinatal <sup>d</sup>	1,896	0.7	908	0.6
Other <sup>e</sup>	4,752	1.7	3,941	2.6
<b>Total<sup>f</sup></b>	<b>280,091</b>	<b>100</b>	<b>154,503</b>	<b>100</b>

*Note.* Deaths of persons with HIV disease, stage 3 (AIDS) may be due to any cause. Data have been statistically adjusted to account for missing transmission category. Cumulative data are from beginning of the epidemic through 2022.

<sup>a</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.

<sup>b</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>c</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV.

<sup>d</sup> Individuals were aged ≥13 years at time of stage 3 classification or death.

<sup>e</sup> Other risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>f</sup> Because column totals for numbers were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.



## Stage 3 (AIDS) Classifications and Deaths (Any Cause) of Persons with Stage 3 (AIDS), by Region of Residence, Cumulative as of Year-End 2022— United States and 6 Territories and Freely Associated States

Region of Residence	Classifications		Deaths	
	No.	%	No.	%
Northeast	363,740	26.9	232,232	28.7
Midwest	143,403	10.6	84,961	10.5
South	547,834	40.6	316,868	39.1
West	259,093	19.2	148,588	18.3
U.S. territories and freely associated states	36,928	2.7	27,717	3.4
<b>Total</b>	<b>1,350,998</b>	<b>100</b>	<b>810,366</b>	<b>100</b>

*Note.* Data are based on residence at time of stage 3 (AIDS) classification or death. Deaths of persons with HIV disease, stage 3 (AIDS) may be due to any cause. Data include persons of all ages. Cumulative data are from the beginning of the epidemic through 2022.





## Stage 3 (AIDS), 2022 and Cumulative, and Persons Living with Diagnosed HIV Ever Classified as Stage 3 (AIDS) (Prevalence), Year-end 2022 by Metropolitan Statistical Area of Residence— United States and Puerto Rico (Slide 1 of 10)

MSA of residence	Classification, 2022 <sup>a</sup>			Classification, cumulative <sup>a,b</sup>			Prevalence of stage 3 (AIDS) year-end 2022 <sup>c</sup>	
	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>	Rank (based on rate) <sup>d</sup>	Persons aged ≥13 years	Children aged <13 years	Total	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>
Akron, OH	26	3.7	70	1,105	1	1,106	512	73.4
Albany-Schenectady-Troy, NY	21	2.3	95	2,764	26	2,790	1,234	136.4
Albuquerque, NM	13	1.4	107	1,940	4	1,944	1,008	109.6
Allentown-Bethlehem-Easton, PA-NJ	10	1.1	—	1,872	18	1,890	939	107.8
Atlanta-Sandy Springs-Alpharetta, GA	738	11.9	3	38,290	156	38,446	19,832	318.7
Augusta-Richmond County, GA-SC	39	6.2	27	2,966	26	2,992	1,373	220.0
Austin-Round Rock-Georgetown, TX	115	4.7	51	6,973	26	6,999	3,185	131.6
Bakersfield, CA	65	7.1	20	2,451	9	2,460	1,033	112.8
Baltimore-Columbia-Towson, MD	175	6.2	28	27,060	228	27,288	8,647	304.9
Baton Rouge, LA	66	7.6	15	6,323	27	6,350	2,627	300.9
Birmingham-Hoover, AL	66	5.9	33	3,918	25	3,943	1,825	163.4
Boise City, ID	13	1.6	105	512	0	512	74	9.1
Boston-Cambridge-Newton, MA-NH	151	3.1	81	18,013	168	18,181	7,306	149.1
Boston, MA	86	4.2	—	11,087	98	11,185	4,271	210.9
Cambridge-Newton-Framingham, MA	62	2.6	—	6,521	69	6,590	2,923	120.6

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Ranks were not assigned to MSAs with rates that were based on reported numbers less than 12.

<sup>a</sup> Data are based on residence at time of classification.      <sup>b</sup> From the beginning of the epidemic through 2022.

<sup>c</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>d</sup> Data include persons of all ages.



## Stage 3 (AIDS), 2022 and Cumulative, and Persons Living with Diagnosed HIV Ever Classified as Stage 3 (AIDS) (Prevalence), Year-end 2022 by Metropolitan Statistical Area of Residence— United States and Puerto Rico (Slide 2 of 10)

MSA of residence	Classification, 2022 <sup>a</sup>			Classification, cumulative <sup>a,b</sup>			Prevalence of stage 3 (AIDS) year-end 2022 <sup>c</sup>	
	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>	Rank (based on rate) <sup>d</sup>	Persons aged ≥13 years	Children aged <13 years	Total	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>
Bridgeport-Stamford-Norwalk, CT								
Buffalo-Cheektowaga, NY	47	4.0	65	3,220	20	3,240	1,301	112.0
Cape Coral-Fort Myers, FL	34	4.1	63	2,508	27	2,535	1,275	155.0
Charleston-North Charleston, SC	49	5.9	34	3,050	25	3,075	1,324	159.4
Charlotte-Concord-Gastonia, NC-SC	234	8.5	9	7,026	32	7,058	4,169	151.3
Chattanooga, TN-GA	31	5.4	41	1,475	3	1,478	682	118.7
Chicago-Naperville-Elgin, IL-IN-WI	466	4.9	48	41,276	270	41,546	14,382	152.3
Chicago-Naperville-Evanston, IL	396	5.6	—	37,652	244	37,896	12,968	182.9
Elgin, IL	23	3.1	—	911	10	921	250	33.3
Gary, IN	24	3.3	—	1,560	11	1,571	634	87.9
Lake County-Kenosha County, IL-WI	23	2.6	—	1,153	5	1,158	530	60.4
Cincinnati, OH-KY-IN	93	4.1	64	4,570	22	4,592	2,262	99.9
Cleveland-Elyria, OH	79	3.8	69	5,977	49	6,026	2,684	130.1
Colorado Springs, CO	27	3.5	76	847	5	852	471	61.5
Columbia, SC	76	9.0	8	5,076	26	5,102	2,296	270.9
Columbus, OH	91	4.2	61	5,493	26	5,519	2,671	123.6

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Ranks were not assigned to MSAs with rates that were based on reported numbers less than 12.

<sup>a</sup> Data are based on residence at time of classification.      <sup>b</sup> From the beginning of the epidemic through 2022.

<sup>c</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>d</sup> Data include persons of all ages.



## Stage 3 (AIDS), 2022 and Cumulative, and Persons Living with Diagnosed HIV Ever Classified as Stage 3 (AIDS) (Prevalence), Year-end 2022 by Metropolitan Statistical Area of Residence— United States and Puerto Rico (Slide 3 of 10)

MSA of residence	Classification, 2022 <sup>a</sup>			Classification, cumulative <sup>a,b</sup>			Prevalence of stage 3 (AIDS) year-end 2022 <sup>c</sup>	
	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>	Rank (based on rate) <sup>d</sup>	Persons aged ≥13 years	Children aged <13 years	Total	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>
Dallas-Fort Worth-Arlington, TX	642	8.1	11	31,055	64	31,119	14,915	187.8
Dallas-Plano-Irving, TX	491	9.2	—	24,482	38	24,520	11,595	216.6
Fort Worth-Arlington, TX	151	5.8	—	6,573	26	6,599	3,320	128.1
Dayton-Kettering, OH	35	4.3	60	1,851	15	1,866	905	111.4
Deltona-Daytona Beach-Ormond Beach, FL	48	6.8	21	2,364	17	2,381	1,247	176.7
Denver-Aurora-Lakewood, CO	174	5.8	36	9,282	27	9,309	3,976	133.2
Des Moines-West Des Moines, IA	18	2.5	91	890	4	894	495	67.9
Detroit-Warren-Dearborn, MI	199	4.6	55	14,800	80	14,880	5,297	121.9
Detroit-Dearborn-Livonia, MI	133	7.6	—	11,384	63	11,447	3,514	200.0
Warren-Troy-Farmington Hills, MI	66	2.5	—	3,416	17	3,433	1,783	68.9
Durham-Chapel Hill, NC	44	6.6	22	2,074	13	2,087	1,117	168.1
El Paso, TX	40	4.6	54	2,394	11	2,405	1,237	141.8
Fayetteville, NC	39	7.4	17	1,695	8	1,703	908	171.5
Fayetteville-Springdale-Rogers, AR	9	1.6	—	534	5	539	300	52.0
Fresno, CA	67	6.6	23	2,515	11	2,526	1,144	112.7
Grand Rapids-Wyoming, MI	19	1.7	104	1,347	7	1,354	644	58.9

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Ranks were not assigned to MSAs with rates that were based on reported numbers less than 12.

<sup>a</sup> Data are based on residence at time of classification.

<sup>b</sup> From the beginning of the epidemic through 2021.

<sup>c</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>d</sup> Data include persons of all ages.



## Stage 3 (AIDS), 2022 and Cumulative, and Persons Living with Diagnosed HIV Ever Classified as Stage 3 (AIDS) (Prevalence), Year-end 2022 by Metropolitan Statistical Area of Residence— United States and Puerto Rico (Slide 4 of 10)

MSA of residence	Classification, 2022 <sup>a</sup>			Classification, cumulative <sup>a,b</sup>			Prevalence of stage 3 (AIDS) year-end 2022 <sup>c</sup>	
	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>	Rank (based on rate) <sup>d</sup>	Persons aged ≥13 years	Children aged <13 years	Total	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>
Greensboro-High Point, NC	45	5.7	38	2,019	19	2,038	1,037	132.3
Greenville-Anderson, SC	54	5.6	40	2,386	7	2,393	1,229	128.2
Harrisburg-Carlisle, PA	18	3.0	82	1,762	9	1,771	761	126.1
Hartford-East Hartford-Middletown, CT								
Honolulu (Urban), HI	23	2.3	97	2,492	14	2,506	819	82.3
Houston-The Woodlands-Sugar Land, TX	696	9.5	4	38,674	183	38,857	16,291	221.9
Huntsville, AL	12	2.3	94	812	6	818	373	72.5
Indianapolis-Carmel-Anderson, IN	131	6.1	30	6,098	28	6,126	2,872	134.1
Jackson, MS	47	8.1	12	4,096	32	4,128	1,567	268.7
Jacksonville, FL	156	9.3	5	9,192	78	9,270	3,988	238.0
Kansas City, MO-KS	88	4.0	66	6,480	18	6,498	2,370	107.3
Knoxville, TN	40	4.4	58	1,468	8	1,476	658	72.5
Lakeland-Winter Haven, FL	58	7.4	18	2,854	23	2,877	1,601	203.3
Lancaster, PA	10	1.8	—	951	22	973	408	73.3
Lansing-East Lansing, MI	13	2.4	92	688	9	697	315	58.2
Las Vegas-Henderson-Paradise, NV	185	8.0	13	7,612	30	7,642	4,389	188.9

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Ranks were not assigned to MSAs with rates that were based on reported numbers less than 12.

<sup>a</sup> Data are based on residence at time of classification. <sup>b</sup> From the beginning of the epidemic through 2022.

<sup>c</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>d</sup> Data include persons of all ages.



## Stage 3 (AIDS), 2022 and cumulative, and persons living with diagnosed HIV ever classified as stage 3 (AIDS) (prevalence), year-end 2022 by metropolitan statistical area of residence— United States and Puerto Rico (Slide 5 of 10)

MSA of residence	Classification, 2022 <sup>a</sup>			Classification, cumulative <sup>a,b</sup>			Prevalence of stage 3 (AIDS) year-end 2022 <sup>c</sup>	
	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>	Rank (based on rate) <sup>d</sup>	Persons aged	Children aged	Total No.	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>
				≥13 years No.	<13 years No.			
Lexington-Fayette, KY	24	4.6	52	1,123	1	1,124	637	123.0
Little Rock-North Little Rock-Conway, AR	33	4.4	59	2,198	14	2,212	984	129.9
Los Angeles-Long Beach-Anaheim, CA	770	6.0	32	76,385	308	76,693	28,290	219.8
Anaheim-Santa Ana-Irvine, CA	114	3.6	—	9,116	46	9,162	3,488	110.7
Los Angeles-Long Beach-Glendale, CA	656	6.7	—	67,269	262	67,531	24,802	255.1
Louisville/Jefferson County, KY-IN	108	8.4	10	3,695	29	3,724	1,783	138.8
Madison, WI	15	2.2	100	740	5	745	386	56.2
McAllen-Edinburg-Mission, TX	33	3.7	71	1,340	13	1,353	852	95.9
Memphis, TN-MS-AR	165	12.4	2	8,299	25	8,324	3,506	263.2
Miami-Fort Lauderdale-Pompano Beach, FL	884	14.4	1	74,054	1,017	75,071	27,393	446.2
Fort Lauderdale-Pompano Beach-Sunrise, FL	306	15.7	—	22,835	268	23,103	10,232	525.5
Miami-Miami Beach-Kendall, FL	412	15.4	—	38,628	516	39,144	12,544	469.1
West Palm Beach-Boca Raton-Boynton Beach, FL	166	10.9	—	12,591	233	12,824	4,617	304.1
Milwaukee-Waukesha, WI	43	2.8	85	3,594	19	3,613	1,545	99.1
Minneapolis-St. Paul-Bloomington, MN-WI	99	2.7	87	6,544	23	6,567	3,421	92.6
Modesto, CA	20	3.6	75	999	6	1,005	470	85.3

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Ranks were not assigned to MSAs with rates that were based on reported numbers less than 12.

<sup>a</sup> Data are based on residence at time of classification.      <sup>b</sup> From the beginning of the epidemic through 2022.

<sup>c</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>d</sup> Data include persons of all ages.



## Stage 3 (AIDS), 2022 and Cumulative, and Persons Living with Diagnosed HIV Ever Classified as Stage 3 (AIDS) (Prevalence), Year-end 2022 by Metropolitan Statistical Area of Residence— United States and Puerto Rico (Slide 6 of 10)

MSA of residence	Classification, 2022 <sup>a</sup>			Classification, cumulative <sup>a,b</sup>			Prevalence of stage 3 (AIDS) year-end 2022 <sup>c</sup>	
	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>	Rank (based on rate) <sup>d</sup>	Persons aged ≥13 years	Children aged <13 years	Total	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>
				No.	No.	No.		
Myrtle Beach-Conway-North Myrtle Beach, SC-NC	28	5.2	45	1,137	3	1,140	635	118.4
Nashville-Davidson-Murfreesboro-Franklin, TN	94	4.6	53	5,676	27	5,703	2,623	128.1
New Haven-Milford, CT								
New Orleans-Metairie, LA	113	9.1	7	12,094	78	12,172	4,062	326.0
New York-Newark-Jersey City, NY-NJ-PA	1,397	7.1	19	230,398	2,954	233,352	72,259	368.3
Nassau County-Suffolk County, NY	85	2.9	—	9,868	118	9,986	3,343	114.9
Newark, NJ-PA	181	8.0	—	24,487	352	24,839	6,238	275.2
New Brunswick-Lakewood, NJ	63	2.5	—	8,239	133	8,372	2,761	110.1
New York-Jersey City-White Plains, NY-NJ	1,068	8.9	—	187,804	2,351	190,155	59,917	502.1
North Port-Sarasota-Bradenton, FL	33	3.7	72	2,680	30	2,710	1,214	136.2
Ogden-Clearfield, UT	6	0.8	—	371	4	375	215	30.1
Oklahoma City, OK	84	5.8	37	3,515	4	3,519	1,453	99.6
Omaha-Council Bluffs, NE-IA	20	2.0	102	1,550	5	1,555	294	30.1
Orlando-Kissimmee-Sanford, FL	253	9.2	6	13,346	95	13,441	6,429	232.6
Oxnard-Thousand Oaks-Ventura, CA	19	2.3	98	1,380	5	1,385	577	69.3
Palm Bay-Melbourne-Titusville, FL	37	5.9	35	2,040	12	2,052	957	151.7
Pensacola-Ferry Pass-Brent, FL	25	4.8	49	2,125	13	2,138	838	160.2

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Ranks were not assigned to MSAs with rates that were based on reported numbers less than 12.

<sup>a</sup> Data are based on residence at time of classification. <sup>b</sup> From the beginning of the epidemic through 2022.

<sup>c</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>d</sup> Data include persons of all ages.



## Stage 3 (AIDS), 2022 and Cumulative, and Persons Living with Diagnosed HIV Ever Classified as Stage 3 (AIDS) (Prevalence), Year-end 2022 by Metropolitan Statistical Area of Residence— United States and Puerto Rico (Slide 7 of 10)

MSA of residence	Classification, 2022 <sup>a</sup>			Classification, cumulative <sup>a,b</sup>			Prevalence of stage 3 (AIDS) year-end 2022 <sup>c</sup>	
	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>	Rank (based on rate) <sup>d</sup>	Persons aged ≥13 years	Children aged <13 years	Total	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>
				No.	No.	No.		
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	380	6.1	31	36,937	320	37,257	13,783	220.8
Camden, NJ	54	4.2	—	4,092	46	4,138	1,524	117.4
Montgomery County-Bucks County-Chester County, PA	45	2.2	—	3,146	11	3,157	1,255	61.1
Philadelphia, PA	243	11.3	—	25,769	237	26,006	9,553	445.9
Wilmington, DE-MD-NJ	38	5.1	—	3,930	26	3,956	1,451	194.6
Phoenix-Mesa-Scottsdale, AZ	270	5.4	42	11,514	37	11,551	5,933	118.3
Pittsburgh, PA	34	1.4	106	4,379	22	4,401	1,909	81.3
Portland-South Portland, ME	13	2.3	96	806	3	809	439	78.2
Portland-Vancouver-Hillsboro, OR-WA	68	2.7	86	6,366	9	6,375	2,878	114.7
Port St. Lucie, FL	39	7.5	16	3,201	41	3,242	1,417	272.1
Poughkeepsie-Newburgh-Middletown, NY	22	3.1	80	3,397	26	3,423	1,075	152.8
Providence-Warwick, RI-MA	34	2.0	103	5,036	44	5,080	1,170	69.9
Provo-Orem, UT	7	1.0	—	188	3	191	117	16.4
Raleigh-Cary, NC	78	5.3	44	3,497	19	3,516	1,906	128.4
Reno, NV	16	3.2	79	1,105	1	1,106	516	103.0

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Ranks were not assigned to MSAs with rates that were based on reported numbers less than 12.

<sup>a</sup> Data are based on residence at time of classification.      <sup>b</sup> From the beginning of the epidemic through 2020.

<sup>c</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>d</sup> Data include persons of all ages.



## Stage 3 (AIDS), 2022 and Cumulative, and Persons Living with Diagnosed HIV Ever Classified as Stage 3 (AIDS) (Prevalence), Year-end 2022 by Metropolitan Statistical Area of Residence— United States and Puerto Rico (Slide 8 of 10)

MSA of residence	Classification, 2022 <sup>a</sup>			Classification, cumulative <sup>a,b</sup>			Prevalence of stage 3 (AIDS) year-end 2022 <sup>c</sup>	
	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>	Rank (based on rate) <sup>d</sup>	Persons aged ≥13 years	Children aged <13 years	Total	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>
Richmond, VA	76	5.7	39	4,997	35	5,032	2,057	153.6
Riverside-San Bernardino-Ontario, CA	240	5.1	47	12,280	64	12,344	8,103	173.6
Rochester, NY	30	2.8	84	3,818	17	3,835	1,524	141.0
Sacramento-Roseville-Folsom, CA	81	3.4	77	5,635	30	5,665	2,748	113.7
St. Louis, MO-IL	126	4.5	57	8,466	43	8,509	3,338	119.2
Salt Lake City, UT	30	2.4	93	2,220	9	2,229	1,045	82.5
San Antonio-New Braunfels, TX	163	6.1	29	7,861	32	7,893	3,734	140.6
San Diego-Chula Vista-Carlsbad, CA	169	5.2	46	16,564	74	16,638	6,902	210.7
San Francisco-Oakland-Berkeley, CA	207	4.5	56	47,228	104	47,332	12,102	264.3
Oakland-Berkeley-Livermore, CA	106	3.8	—	12,619	53	12,672	4,634	166.3
San Francisco-San Mateo-Redwood City, CA	94	6.1	—	32,881	46	32,927	7,040	457.9
San Jose-Sunnyvale-Santa Clara, CA	56	2.9	83	5,132	17	5,149	1,897	97.9
San Juan-Carolina-Caguas, PR	109	5.3	43	25,554	281	25,835	5,540	271.0
Scranton-Wilkes-Barre, PA	27	4.8	50	813	6	819	505	88.9
Seattle-Tacoma-Bellevue, WA	149	3.7	73	11,935	27	11,962	4,878	120.9
Seattle-Bellevue-Kent, WA	114	3.7	—	10,468	18	10,486	4,043	130.1
Tacoma-Lakewood, WA	35	3.8	—	1,467	9	1,476	835	90.0

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Ranks were not assigned to MSAs with rates that were based on reported numbers less than 12.

<sup>a</sup> Data are based on residence at time of classification.      <sup>b</sup> From the beginning of the epidemic through 2022.

<sup>c</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>d</sup> Data include persons of all ages.





## Stage 3 (AIDS), 2022 and Cumulative, and Persons Living with Diagnosed HIV Ever Classified as Stage 3 (AIDS) (Prevalence), Year-end 2022 by Metropolitan Statistical Area of Residence— United States and Puerto Rico (Slide 9 of 10)

MSA of residence	Classification, 2022 <sup>a</sup>			Classification, cumulative <sup>a,b</sup>			Prevalence of stage 3 (AIDS) year-end 2022 <sup>c</sup>	
	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>	Rank (based on rate) <sup>d</sup>	Persons aged ≥13 years	Children aged <13 years	Total	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>
Spokane-Spokane Valley, WA	13	2.2	101	727	1	728	393	65.7
Springfield, MA	23	3.3	78	2,789	29	2,818	1,196	172.2
Stockton, CA	33	4.2	62	1,673	15	1,688	754	95.1
Syracuse, NY	17	2.6	90	1,698	10	1,708	680	104.0
Tampa-St. Petersburg-Clearwater, FL	251	7.6	14	16,184	118	16,302	7,391	224.6
Toledo, OH	17	2.7	88	1,229	14	1,243	572	89.3
Tucson, AZ	39	3.7	74	2,707	13	2,720	1,344	127.1
Tulsa, OK	41	4.0	67	2,178	13	2,191	991	95.8
Virginia Beach-Norfolk-Newport News, VA-NC	114	6.3	26	7,118	67	7,185	2,553	141.3
Washington-Arlington-Alexandria, DC-VA-MD-WV	414	6.5	24	43,670	338	44,008	17,669	277.2
Frederick-Gaithersburg-Rockville, MD	56	4.2	—	4,598	24	4,622	2,233	166.7
Washington-Arlington-Alexandria, DC-VA-MD-WV	358	7.1	—	39,072	314	39,386	15,436	306.6

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Ranks were not assigned to MSAs with rates that were based on reported numbers less than 12.

<sup>a</sup> Data are based on residence at time of classification. <sup>b</sup> From the beginning of the epidemic through 2022.

<sup>c</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>d</sup> Data include persons of all ages



## Stage 3 (AIDS), 2022 and Cumulative, and Persons Living with Diagnosed HIV Ever Classified as Stage 3 (AIDS) (Prevalence), Year-end 2022 by Metropolitan Statistical Area of Residence— United States and Puerto Rico (Slide 10 of 10)

MSA of residence	Classification, 2022 <sup>a</sup>			Classification, cumulative <sup>a,b</sup>			Prevalence of stage 3 (AIDS) year-end 2022 <sup>c</sup>	
	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>	Rank (based on rate) <sup>d</sup>	Persons aged ≥13 years	Children aged <13 years	Total	No. <sup>d</sup>	Rate (per 100,000) <sup>d</sup>
Wichita, KS	17	2.6	89	1,123	2	1,125	487	74.9
Winston-Salem, NC	44	6.4	25	1,683	12	1,695	924	134.2
Worcester, MA-CT	19	2.2	99	2,409	21	2,430	1,123	130.1
Youngstown-Warren-Boardman, OH-PA	21	3.9	68	856	1	857	435	81.2
<b>Subtotal for MSAs (population ≥500,000)</b>	<b>13,425</b>	<b>5.8</b>	<b>—</b>	<b>1,123,346</b>	<b>8,575</b>	<b>1,131,921</b>	<b>436,826</b>	<b>189.8</b>
<b>Metropolitan areas (population of 50,000–499,999)</b>	<b>2,090</b>	<b>3.6</b>	<b>—</b>	<b>124,552</b>	<b>804</b>	<b>125,356</b>	<b>54,352</b>	<b>94.7</b>
<b>Nonmetropolitan areas</b>	<b>1,200</b>	<b>2.6</b>	<b>—</b>	<b>70,372</b>	<b>430</b>	<b>70,802</b>	<b>31,070</b>	<b>68.5</b>
<b>Total<sup>e</sup></b>	<b>16,861</b>	<b>5.0</b>	<b>—</b>	<b>1,339,989</b>	<b>10,027</b>	<b>1,350,016</b>	<b>540,971</b>	<b>159.1</b>

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Ranks were not assigned to MSAs with rates that were based on reported numbers less than 12.

<sup>a</sup> Data are based on residence at time of classification. <sup>b</sup> From the beginning of the epidemic through 2022.

<sup>c</sup> Data are based on address of residence at the end of the specified year (i.e., most recent known address).

<sup>d</sup> Data include persons of all ages.

<sup>e</sup> Includes persons whose county of residence is unknown.

